Global Information
회사소개 | 문의 | 위시리스트

주목 시장 분석 : 중피종

Market Spotlight: Mesothelioma

리서치사 Datamonitor Healthcare
발행일 2020년 01월 상품 코드 573553
페이지 정보 영문 38 Pages
가격
US $ 1,318 ₩ 1,604,000 PDF by E-mail (Single User License)


주목 시장 분석 : 중피종 Market Spotlight: Mesothelioma
발행일 : 2020년 01월 페이지 정보 : 영문 38 Pages

세계 45세 이상 인구에서 중피종 이환자수는 2017년 18,900건에 이른 것으로 추정되며, 2026년에는 22,690건으로 증가할 전망입니다. 지역별로는 오세아니아의 이환자수가 가장 많으며, 라틴아메리카 및 카리브해 지역이 가장 적은 것으로 보입니다. 임상개발 중인 약제의 대부분은 2상 임상시험 중이며, 표적은 다양합니다. 개발중인 약제의 대부분은 정맥주사제이며, 그 외에 근육주사제, 경구제, 종양내 약제, 경피 카테터/주사제, 피하 제제 등이 있습니다. 지역별로 임상시험은 미국에서 가장 많이 행해지고 있고, EU에서는 영국이, 아시아에서는 일본이 최고 지위를 차지하고 있습니다.

세계의 중피종(Mesothelioma) 시장을 조사했으며, 질환의 배경 및 개요, 이환자수 10개년 예측, 파이프라인 의약품 및 출시 의약품 개요, 임상시험 상황, 라이선싱/자산 인수 등의 주요 거래 동향, 특허 정보, 주요 약제 매출 예측 등의 정보를 정리하여 전해드립니다.

개요

요점

질환의 배경

치료

  • 외과 수술
  • 화학요법
  • 방사선 요법

역학

출시 의약품

파이프라인 의약품

최근의 이벤트 및 애널리스트의 견해

  • Optune
  • SEL-403
  • Tazemetostat

향후 이벤트

주요 규제 이벤트

라이선싱 및 자산 취득 계약

성공 확률

원특허권(Parent Patent)

매출 기회

임상시험 환경

  • 스폰서 : 진행 상황별
  • 스폰서 : 단계별
  • 최근 전개

문헌

부록

LSH 20.02.12

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Mesothelioma is an aggressive and rare form of cancer which develops in the lining of the heart, lungs, or abdomen. Exposure to asbestos is the primary cause of the disease. The inhalation or swallowing of asbestos leads to an accumulation in the lining of the lungs or the abdomen, causing damage to the tissue. This, in turn, leads to damage to the cells' DNA, and uncontrolled cell growth.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were 18,900 incident cases of mesothelioma in adults aged 45 years and older worldwide, and forecasts that number to increase to 22,690 incident cases by 2026. Oceania is estimated to have the highest disease incidence (2.85 per 100,000 males, and 0.50 per 100,000 females), while Latin America and the Caribbean has the lowest incidence (0.29 per 100,000 males, and 0.17 per 100,000 females).

The approved drugs in the mesothelioma space target thymidylate synthase, the immune system, programmed death-1 receptor/programmed death ligands, and dihydrofolate reductase. All of the approved drugs are administered via the intravenous route.

The majority of industry-sponsored drugs in active clinical development for mesothelioma are in Phase II. Therapies in the mesothelioma space focus on a wide variety of targets. The majority of drugs in development for mesothelioma are administered via the intravenous route, with the remainder being intramuscular, oral, intratumoral, percutaneous catheter/injection, and subcutaneous formulations.

The only high-impact upcoming event for drugs in the mesothelioma space is topline Phase II trial results for Zepsyre. The overall likelihood of approval of a Phase I mesothelioma asset is 6.3%, and the average probability a drug advances from Phase III is 33.3%. Drugs, on average, take 14.8 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There have been seven licensing and asset acquisition deals involving mesothelioma drugs during 2014-19. The $475m licensing agreement signed in 2017 between Calithera Biosciences and Incyte to research, develop, and commercialize Calithera's CB-1158 was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials have been in the early and mid-phases of development, with 95% of trials in Phase I-II, and only 5% in Phase III-IV.

The US has a substantial lead in the number of mesothelioma clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the mesothelioma space is dominated by completed trials. Eli Lilly has the highest number of completed clinical trials for mesothelioma, with 44 trials. Eli Lilly also leads industry sponsors with the highest overall number of clinical trials for mesothelioma.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Surgery
  • Chemotherapy
  • Radiotherapy

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Optune for Mesothelioma (April 02, 2019)
  • SEL-403 for Mesothelioma (October 17, 2018)
  • Tazemetostat for Mesothelioma (September 24, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • US FDA Greenlights First-In-Kind Diagnostics, Device

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of mesothelioma, 2017-26
  • Figure 2: Overview of pipeline drugs for mesothelioma in the US
  • Figure 3: Pipeline drugs for mesothelioma, by company
  • Figure 4: Pipeline drugs for mesothelioma, by drug type
  • Figure 5: Pipeline drugs for mesothelioma, by classification
  • Figure 6: Key upcoming events in mesothelioma
  • Figure 7: Probability of success in the mesothelioma pipeline
  • Figure 8: Licensing and asset acquisition deals in mesothelioma, 2015-20
  • Figure 9: Parent patents in mesothelioma
  • Figure 10: Clinical trials in mesothelioma
  • Figure 11: Top 10 drugs for clinical trials in mesothelioma
  • Figure 12: Top 10 companies for clinical trials in mesothelioma
  • Figure 13: Trial locations in mesothelioma
  • Figure 14: Mesothelioma trials status
  • Figure 15: Mesothelioma trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of mesothelioma, 2017-26
  • Table 2: Incidence rates of mesothelioma, 2017-26
  • Table 3: Marketed drugs for mesothelioma
  • Table 4: Pipeline drugs for mesothelioma in the US
  • Table 5: Optune for Mesothelioma (April 02, 2019)
  • Table 6: SEL-403 for Mesothelioma (October 17, 2018)
  • Table 7: Tazemetostat for Mesothelioma (September 24, 2018)
  • Table 8: Historical global sales, by drug ($m), 2014-18
  • Table 9: Forecasted global sales, by drug ($m), 2020-24
Back to Top
전화 문의
F A Q